Therapy and clinical trials: fibrate therapy in type 2 diabetes - where are we now?

被引：1

作者：

Peter, Rajesh ^{[1
]}

Reilly, Elizabeth

Anthony, Sony ^{[2
]}

机构：

[1] Neath Port Talbot Hosp, Dept Endocrinol & Diabet, Abertawe Bro Morgannwg Univ Hlth Board, Port Talbot SA12 7BX, Wales

[2] N Tees & Hartlepool NHS Trust, Univ Hosp Hartlepool, Hartlepool, England

来源：

CURRENT OPINION IN LIPIDOLOGY | 2010年 / 21卷 / 06期

关键词：

RANDOMIZED CONTROLLED-TRIAL; FENOFIBRATE; PROGRESSION; MELLITUS;

D O I：

10.1097/MOL.0b013e3283404ff1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：554 / 555

页数：2

共 8 条

[1] Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS) [J].

Ansquer, JC ;

Foucher, C ;

Rattier, S ;

Taskinen, MR ;

Steiner, G .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) :485-493

[2] Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. [J].

Chew, Emily Y. ;

Ambrosius, Walter T. ;

Davis, Matthew D. ;

Danis, Ronald P. ;

Gangaputra, Sapna ;

Greven, Craig M. ;

Hubbard, Larry ;

Esser, Barbara A. ;

Lovato, James F. ;

Perdue, Letitia H. ;

Goff, David C., Jr. ;

Cushman, William C. ;

Ginsberg, Henry N. ;

Elam, Marshall B. ;

Genuth, Saul ;

Gerstein, Hertzel C. ;

Schubart, Ulrich ;

Fine, Lawrence J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03) :233-244

[3] Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? [J].

Drexel, Heinz .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 (06) :687-692

[4] Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes - The FIELD Helsinki substudy [J].

Forsblom, Carol ;

Hiukka, Anne ;

Leinonen, Eeva S. ;

Sundvall, Jouko ;

Groop, Per-Henrik ;

Taskinen, Marja-Riitta .

DIABETES CARE, 2010, 33 (02) :215-220

[5]

Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282

[6] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[7] Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial [J].

Keech, A. C. ;

Mitchell, P. ;

Summonen, P. A. ;

O'Day, J. ;

Davis, T. M. E. ;

Moffitt, M. S. ;

Taskinen, M. R. ;

Simes, R. J. ;

Tse, D. ;

Williamson, E. ;

Merrifield, A. ;

Laatikainen, L. T. ;

d'Emden, M. C. ;

Crimet, D. C. ;

O'Connell, R. L. ;

Colman, P. G. .

LANCET, 2007, 370 (9600) :1687-1697

[8] Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors [J].

Lalloyer, Fanny ;

Staels, Bart .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (05) :894-899

← 1 →